title: [Effect of BD Regimen Combined with Cyclophosphamide and Pirarubicin in Treatment of Relapse/Refractory Multiple Myeloma].
abstract: OBJECTIVE
  To compare the efficacy and safety of BD regimen combined with cyclophosphamide(CTX) and pirarubicin chemotherapy(P-CAD) for patients with relapse/refractory multiple myeloma(MM).
  
  
  METHODS
  Twenty-eight cases of relapse/refractory MM were enrolled in a group of P-CAD regimen, 36 cases of relapse/retractory MM treated with BD were used as controls. The therapeutic efficacy and adverse reactions of 2 regimens for patients with relapse/retractory MM were compared and analyzed.
  
  
  RESULTS
  The overall response rate (CR+NCR+PR+MR) of the 28 cases treated with P-CAD regimen was 85.7%, and the response rate (CR+PR) was 75.0%. The median progression-free survival time were 16.1 months, and the average survival time were 30.6 months, while the overall response rate of the 36 patients treated with BD regimen was 63.9%, and the response rate was 55.6%. The median progression-free survival time were 13.7 months, and the average survival time were 26.7 months. The adverse reactions of 2 groups included gastrointestinal reactions, peripheral neuropathy, fatigue, skin rashes, leucopenia and thrombocytopenia, and they were all well tolerated.
  
  
  CONCLUSIONS
  BD regimen combined with cyclophosphamide and pirarubicin chemotherapy can improve the response rate of patients with relapse/refractory multiple myeloma, and shows the trend of prolonging PFS and survival times. Patients were well tolerated, and this regimen is a new choice in treatment of relapse/refractory MM.
authors: Depatment of Haematoloy, Weifang Medical College,Weifang 261042, Shandong Province, China.
authors: Yu-Fen
authors: YF
authors: Wang
authors: Department of Hematology, Weifang Municipal People's Hospital, Weifang 261042, Shandong Province, China.
authors: Wen-Jun
authors: WJ
authors: Xu
authors: Depatment of Haematoloy, Weifang Medical College,Weifang 261042, Shandong Province, China.
authors: Yu-Li
authors: YL
authors: Chen
authors: Depatment of Haematoloy, Weifang Medical College,Weifang 261042, Shandong Province, China.
authors: Xiao-Huan
authors: XH
authors: Ma
authors: Depatment of Haematoloy, Weifang Medical College,Weifang 261042, Shandong Province, China.
authors: Zhi-Yuan
authors: ZY
authors: Qiu
authors: Depatment of Haematoloy, Weifang Medical College, Department of Hematology, Weifang Municipal People's Hospital, Weifang 261042, Shandong Province, China. E-mail:rencuiai@sina.com.
authors: Cui-Ai
authors: CA
authors: Ren
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D003520:Cyclophosphamide; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000031:analogs & derivatives; D006801:Humans; D008130:Lomustine; D009101:Multiple Myeloma; D009364:Neoplasm Recurrence, Local; D014751:Vindesine
chemical_list: D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; C027260:pirarubicin; D014751:Vindesine